HUM vs CLOV

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 11, 2026

HUM

48.5
AI Score
VS
HUM Wins

CLOV

44.1
AI Score

Investment Advisor Scores

HUM

49score
Recommendation
HOLD

CLOV

44score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric HUM CLOV Winner
Revenue 39.65B 1.49B HUM
Net Income 1.19B 55.34M HUM
Net Margin 3.0% 3.7% CLOV
Operating Income 1.75B 55.34M HUM
ROE 6.4% 14.7% CLOV
ROA 2.1% 7.7% CLOV
Total Assets 55.28B 720.33M HUM
Current Ratio 1.77 1.50 HUM
Free Cash Flow 1.13B 131.55M HUM

Relative Price Performance (Last 90 Days)

HUM 1M: +5.4% · 3M: +11.2% CLOV 1M: +6.2% · 3M: -1.6%

Current Technical Phase

HUM

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.5% over 20 days), RSI 63

RSI (14): 63.2 · Price: $409.80

CLOV

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 66

RSI (14): 66.4 · Price: $4.82

Fundamentals Snapshot

Metric HUM CLOV
Market Cap
Forward P/E 24.7 32.1
Trailing P/E 37.9
Revenue (TTM)
Revenue Growth 0.3% 0.6%
Gross Margin 0.1% 0.2%
Operating Margin 0.0% 0.0%
EPS 10.56 -0.05
Dividend Yield 0.01%

Frequently Asked Questions

Based on our detailed analysis, HUM is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.